Author Archives: Denise Bell

President Trump issued a new “Most-Favored-Nations” (MFN) executive order on September 13 that links U.S.-paid Medicare drug prices to those paid by other foreign countries. BIO President and CEO, Dr. Michelle McMurry-Heath, called the President’s action a “reckless scheme” that would hurt vulnerable seniors. The new order includes both Medicare Part B and Part D […]

In a double header of good news, Salt Lake City -based Recursion announced on Wednesday that the company has entered into a strategic collaboration agreement with Bayer to discover and develop new treatments for fibrotic diseases of the lung, kidney, heart and more. The agreement leverages Recursion’s AI drug discovery platform and Bayer’s small molecule […]

HHS said yesterday that it has determined that the FDA will not require premarket review of laboratory-developed tests (LDTs) without notice-and-comment rulemaking. This means that the FDA cannot expand its authority over LDTs through guidance and other informal issuances. As reported by Genome Web, it also means that laboratories will be able to “offer LDTs […]

On August 11, Altitude Lab, founded by BioUtah member Recursion and the University of Utah’s Center for Technology & Venture Commercialization (TVC),  announced its first resident companies and opened applications for its unique collaborative facility and program. The incubator, a state-of-the-art 14,500 square foot lab facility, will offer resident companies workshops, mentoring, and non-dilutive funding […]